No profile data available.
Rein Therapeutics Inc. (RNTX) is a healthcare company in the lung treatment pharmaceuticals industry, based in Austin, United States, with about 10 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$49.87 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $68.50 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Rein Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$68.50 million as of October 9, 2026.
Listed companies of a similar size in the same industry (lung treatment pharmaceuticals) include 4D Molecular Therapeutics, Inc. (FDMT), Upstream Bio, Inc. (UPB), Sionna Therapeutics, Inc. (SION), Pliant Therapeutics, Inc. (PLRX).